Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

6.20USD
23 Feb 2018
Change (% chg)

$0.14 (+2.31%)
Prev Close
$6.06
Open
$6.07
Day's High
$6.31
Day's Low
$6.06
Volume
13,940
Avg. Vol
160,733
52-wk High
$12.80
52-wk Low
$3.10

Select another date:

Tue, Feb 13 2018

BRIEF-Pain Therapeutics Resubmits New Drug Application For Remoxy ER

* PAIN THERAPEUTICS RESUBMITS NEW DRUG APPLICATION FOR REMOXY® ER, AN ABUSE-DETERRENT, EXTENDED-RELEASE DRUG CANDIDATE FOR THE TREATMENT OF CHRONIC PAIN

BRIEF-Pain Therapeutics Signs On Demand Sales Agreement With JonesTrading Institutional Services

* PAIN THERAPEUTICS SAYS ON FEB 8, CO ENTERED INTO AN ATM CAPITAL ON DEMAND SALES AGREEMENT WITH JONESTRADING INSTITUTIONAL SERVICES LLC - SEC FILING

BRIEF-Pain Therapeutics Inc QTRLY ‍Net Loss Per Share $0.37​

* PAIN THERAPEUTICS INC QTRLY ‍NET LOSS PER SHARE $0.37​ Source text: [http://bit.ly/2nGTz7J] Further company coverage:

BRIEF-Pain Therapeutics Reports Positive Results From Nasal Abuse Potential Study With Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE TOP-LINE RESULTS FROM NASAL ABUSE POTENTIAL STUDY WITH REMOXY™

BRIEF-Pain Therapeutics Reports Positive Regulatory Meeting For Remoxy

* PAIN THERAPEUTICS REPORTS POSITIVE REGULATORY MEETING FOR REMOXY™

BRIEF-Pain therapeutics reports Q3 loss per share $0.40

* Pain therapeutics reports third quarter 2017 financial results

BRIEF-Pain Therapeutics announces upcoming meeting with FDA

* Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​

BRIEF-Pain Therapeutics announces successful Phase I clinical study for PTI-125

* Pain Therapeutics announces successful Phase I clinical study for PTI-125

BRIEF-National Institute on Drug Abuse awards Pain Therapeutics $2.2 mln grant

* National Institute on Drug Abuse awards Pain Therapeutics $2.2 million grant Source text for Eikon: Further company coverage:

Select another date: